[Clinical studies of cefoperazone in the treatment of pyoderma (author's transl)].
Cefoperazone (CPZ), a new semisynthetic cephalosporin derivative, was administered in the treatment of pyoderma. The results are shown as follows. CPZ was given to 21 patients with pyoderma. In 21 patients, marked improvement was seen in 7, effectiveness in 10, slight improvement in 1 and ineffective in 3. Total clinical effectiveness rate was 81.0%. No serious side effects were observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002438:Cefoperazone; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011711:Pyoderma / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects
D002511:Cephalosporins; D002438:Cefoperazone